Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients

Rhea-AI Summary

Counterpart Health (Nasdaq: CLOV) released a whitepaper showing use of Counterpart Assistant (CA) clinical insights linked to higher flu vaccination rates and fewer flu-related acute care events among Medicare Advantage patients with chronic disease.

Key results: CA PCPs had 1.39x vaccination odds; provider completion of the flu insight raised odds to 1.89x. CA relationships correlated with 17% lower COPD acute-event incidence and 11% lower CHF incidence, plus 22% fewer COPD encounters and 18% fewer CHF encounters.

Positive

• Vaccination odds 1.39x for patients of CA PCPs
• Engaged-provider effect vaccination odds 1.89x when flu insight completed
• COPD incidence 17% lower flu-related acute-event rate
• CHF incidence 11% lower flu-related acute-event rate
• COPD encounters 22% fewer flu-related acute care encounters
• CHF encounters 18% fewer flu-related acute care encounters

Negative

• Benefit depends on clinician engagement — vaccination gains tied to providers completing the in-platform flu insight

Key Figures

Flu vaccination likelihood vs CA cohort: 1.89 times more likely Flu vaccination likelihood vs Non-CA: 1.39 times more likely Flu-related hospitalizations share: 90%–95% +5 more

8 metrics

Flu vaccination likelihood vs CA cohort 1.89 times more likely Patients whose providers completed in-platform flu insight vs other CA PCPs

Flu vaccination likelihood vs Non-CA 1.39 times more likely Patients with CA-using PCPs vs Non-CA cohort

Flu-related hospitalizations share 90%–95% Flu-related hospitalizations occurring in adults with chronic conditions

COPD acute event incidence reduction 17% lower incidence rate Patients with COPD seeing at least one flu-related acute care event

CHF acute event incidence reduction 11% lower incidence rate Patients with CHF seeing at least one flu-related acute care event

COPD encounter volume reduction 22% fewer encounters Flu-related acute care encounters among COPD patients

CHF encounter volume reduction 18% fewer encounters Flu-related acute care encounters among CHF patients

Overall encounter reduction range 18%–22% fewer events Flu-related acute care events among COPD and CHF patients

Market Reality Check

Price: $1.88 Vol: Volume 6,933,423 is 1.19x...

normal vol

$1.88 Last Close

Volume Volume 6,933,423 is 1.19x the 20-day average of 5,834,271, indicating elevated trading activity ahead of this news. normal

Technical Shares at $1.88 are trading below the $2.66 200-day MA and sit near the $1.86 52-week low, well off the $3.92 52-week high.

Peers on Argus

CLOV fell 2.59% while peers were mixed: PGNY -1%, ALHC +1.56%, OSCR +2.42%, NEUE...

CLOV fell 2.59% while peers were mixed: PGNY -1%, ALHC +1.56%, OSCR +2.42%, NEUE -0.69%, MOH +3.94%. This pattern points to stock-specific factors rather than a broad Healthcare Plans sector move.

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Tech interoperability	Positive	-0.5%	Went live on Kno2 interoperability network using FHIR standards.
Mar 04	Network milestone	Positive	+8.0%	First payer live on CMS aligned network and TEFCA for data exchange.
Feb 26	Earnings & guidance	Positive	-2.8%	Strong 2025 growth and 2026 guidance toward positive GAAP net income.
Feb 17	Conference appearance	Neutral	+2.5%	Announcement of participation in Leerink 2026 Global Healthcare Conference.
Jan 29	Earnings date set	Neutral	-1.3%	Scheduled date and webcast details for Q4 and full-year 2025 results.

Pattern Detected

Recent news and earnings often read positively but have produced mixed to slightly negative next-day moves, especially around major guidance updates.

Recent Company History

Over the last few months, Clover Health has highlighted technology-driven improvements and growth. On Feb 26, 2026, it reported $1.924B 2025 revenue and guided to higher 2026 membership, revenue, and potential positive GAAP net income, yet shares fell. March news emphasized interoperability and being first live on a CMS-aligned network, again with modest and mixed reactions. Today’s Counterpart Assistant outcomes data extends this tech-and-outcomes narrative within its Medicare Advantage focus.

Market Pulse Summary

This announcement highlights Counterpart Assistant’s impact on flu prevention in high-risk COPD and ...

Analysis

This announcement highlights Counterpart Assistant’s impact on flu prevention in high-risk COPD and CHF Medicare Advantage patients, with 18%–22% fewer flu-related acute care events and higher vaccination rates for those tied to CA-using PCPs. It reinforces Clover’s technology-driven, value-based care strategy showcased in recent interoperability initiatives and earnings commentary. Investors may track further data on utilization, chronic disease outcomes, and adoption of CA across Medicare populations.

Key Terms

chronic obstructive pulmonary disease, copd, congestive heart failure, medicare advantage, +3 more

7 terms

chronic obstructive pulmonary disease medical

"For patients with chronic obstructive pulmonary disease (COPD), such a relationship..."

Chronic obstructive pulmonary disease (COPD) is a long-lasting lung condition that makes breathing progressively harder by narrowing airways and destroying air sacs, like an increasingly clogged and leaky air pipe. It matters to investors because COPD represents a large, growing market for treatments, diagnostics and medical devices, influences healthcare spending and insurance costs, and is a frequent focus of regulatory reviews and clinical trials that can materially affect company value.

copd medical

"For patients with chronic obstructive pulmonary disease (COPD), such a relationship..."

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that progressively narrows airways and reduces the ability to breathe, causing persistent cough, shortness of breath and fatigue. It matters to investors because a large and growing patient population creates steady demand for drugs, medical devices and care services, influences healthcare spending and regulatory decisions, and offers clear market opportunities—similar to a leaking engine that requires ongoing fixes and replacement parts.

congestive heart failure medical

"Similarly, for patients with congestive heart failure (CHF), such a relationship..."

A chronic condition in which the heart cannot pump blood efficiently enough to meet the body's needs, causing fluid buildup in the lungs and tissues; think of the heart as a weakened pump that lets pressure and fluid back up into pipes. It matters to investors because it drives demand for medications, medical devices, hospital services and long‑term care, influences healthcare spending and clinical trial activity, and can materially affect the revenue and regulatory risk for companies developing treatments.

medicare advantage medical

"within Clover Health’s Medicare Advantage (MA) population."

Medicare Advantage is a type of health insurance plan offered by private companies that covers services traditionally provided by government-run Medicare. Think of it as a bundled package that combines hospital, doctor, and other medical care into one plan, often with added benefits. For investors, it matters because the popularity and profitability of these plans can influence healthcare companies and the broader health insurance industry.

emergency department medical

"difference in hospitalizations and emergency department visits strongly suggests that CA..."

A hospital’s emergency department is the 24/7 clinical unit that evaluates and treats people with urgent or life‑threatening conditions, acting like the hospital’s front door for immediate care. For investors, its volume and performance signal demand for healthcare services, affect hospital revenue and cost patterns, and influence regulatory and reimbursement risks—similar to how customer foot traffic informs the health of a retail business.

value-based care medical

"It’s a scalable model enabling effective value-based care."

A health-care delivery approach that rewards providers for keeping patients healthy and improving outcomes instead of charging for each test or visit. For investors, it matters because it shifts where profits and losses come from—favoring providers and technologies that lower long-term costs, prevent complications, and demonstrate measurable results; think of it like paying a contractor only when the house stays sound, which changes who wins and loses financially.

clinical guidelines medical

"By fusing dozens of health-data streams with up-to-date clinical guidelines, CA delivers..."

Clinical guidelines are systematically developed recommendations from medical experts that outline the best ways to diagnose, treat, and manage specific health conditions; think of them as a trusted recipe or roadmap for doctors to follow. Investors care because these guidelines shape which tests, drugs, and devices become standard practice, driving demand, pricing, and insurance coverage — changes that can significantly affect a healthcare company's revenue and market value.

AI-generated analysis. Not financial advice.

New Counterpart Health whitepaper finds patients whose primary care physicians (PCP) used Counterpart Assistant’s flu-related clinical insight were 1.89 times more likely to receive a flu vaccination — and patients with COPD and CHF experienced significantly fewer flu-related hospitalizations and emergency visits

SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), and a leading AI-powered physician-enablement platform today released a whitepaper titled “Driving Clinical Excellence in Chronic Disease: Counterpart Assistant’s Role in Flu Preventative Care.” The analysis examines the role of CA’s real-time clinical insights on immunization rates and flu-related acute care utilization within Clover Health’s Medicare Advantage (MA) population.

Influenza remains a major cause of morbidity among Medicare beneficiaries, with 90% to 95% of flu-related hospitalizations occurring in adults with underlying chronic conditions. For vulnerable populations, a single respiratory infection can lead to permanent functional decline. By fusing dozens of health-data streams with up-to-date clinical guidelines, CA delivers real-time recommendations that help Primary Care Physicians (PCPs) mitigate these risks.

Key highlights from the whitepaper:

• CA promotes preventive care insights at the point of care by identifying patients eligible for flu vaccination and providing clinical recommendations to the provider. Analysis indicates that patients having a relationship with a PCP that uses CA (CA PCPs) were 1.39 times more likely to be vaccinated than those in the Non-CA cohort. Furthermore, patients whose providers completed the in-platform flu insight were 1.89 times more likely to be vaccinated than those in the CA cohort whose providers did not engage with the task.
• A relationship with a CA PCP was also associated with a lower rate of flu-related acute care utilization (inpatient hospitalizations and ED visits) for patients with certain high-risk chronic diseases. For patients with chronic obstructive pulmonary disease (COPD), such a relationship was associated with a 17% lower incidence rate of a patient experiencing at least one flu-related acute care event. Similarly, for patients with congestive heart failure (CHF), such a relationship was associated with an 11% lower incidence rate.
• A relationship with a CA PCP was also associated with a lower total volume of flu-related acute care encounters across these high-risk groups. For COPD patients, such a relationship was associated with 22% fewer flu-related acute care encounters. Similarly, for congestive heart failure patients, such a relationship was associated with 18% fewer flu-related encounters.
  
  

“This analysis shows what happens when primary care physicians have timely, actionable information at the point of care,” said Dr. David Tsay, MD, PhD, Chief Medical Officer at Counterpart Health and co-author of the whitepaper. “By prompting preventive action during the visit, CA helps clinicians increase immunization rates and reduce avoidable acute events, particularly for patients with complex chronic conditions.”

The data also reflects a lower incidence rate and lower total volume of flu-related acute care utilization among COPD and CHF patients attributed to a PCP who utilizes CA. This notable difference in hospitalizations and emergency department visits strongly suggests that CA helps support a crucial shift toward proactive and longitudinal care strategies. By helping PCPs reduce the incidence rate of acute events, CA enables lower clinical risk for adverse outcomes in vulnerable populations where a single respiratory infection can lead to permanent functional decline.

“The reductions in flu-related hospitalizations and emergency visits among high-risk patients reflect what we’ve seen within Clover Health’s Medicare Advantage population,” said Conrad Wai, CEO of Counterpart Health. “Equipping primary care with timely, actionable insights enables earlier intervention, fewer avoidable acute events, and lower total cost of care. It’s not plan-specific. It’s a scalable model enabling effective value-based care."

Counterpart Health continues to expand CA’s capabilities to support preventive care, chronic disease management, and value-based performance across Medicare populations. By embedding actionable intelligence directly into the clinical workflow, CA enables plans and providers to shift from reactive treatment to proactive care.

To learn more about Counterpart Health, visit: www.counterparthealth.com.

About Counterpart Health

Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes, Chronic Kidney Disease, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease management, as well as Clinical Quality and Underserved Patient Populations.

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale.
Visit: www.cloverhealth.com

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

FAQ

How did Counterpart Assistant use affect flu vaccination rates in Clover Health (CLOV) Medicare Advantage patients?

Patients of PCPs using CA were 1.39 times more likely to be vaccinated; provider completion increased odds to 1.89x. According to the company, CA identifies eligible patients and prompts clinicians with real-time flu vaccination recommendations at point of care.

What impact did Counterpart Assistant have on flu-related hospitalizations for COPD patients in the CLOV study?

CA PCP relationships were associated with a 17% lower incidence of at least one flu-related acute care event for COPD patients. According to the company, CA also corresponded to 22% fewer total flu-related encounters in this group.

What were the measured effects of Counterpart Assistant on CHF patients' acute care in the CLOV analysis?

A CA PCP relationship correlated with an 11% lower incidence rate for flu-related acute events among CHF patients. According to the company, CA use was also linked to 18% fewer total flu-related acute care encounters for CHF.

Does the whitepaper say the vaccination benefit requires clinician action for CLOV's Counterpart Assistant?

Yes — vaccination odds rose to 1.89x when the provider completed the in-platform flu insight versus CA providers who did not. According to the company, completion of the task drives the stronger effect on immunization rates.

How does Counterpart Assistant deliver flu prevention support to PCPs in CLOV's Medicare Advantage population?

CA fuses multiple health-data streams with current guidelines to generate real-time, point-of-care recommendations identifying patients eligible for flu vaccination. According to the company, these insights prompt clinicians to take preventive action during visits.